SG11201610731VA - A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection - Google Patents

A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection

Info

Publication number
SG11201610731VA
SG11201610731VA SG11201610731VA SG11201610731VA SG11201610731VA SG 11201610731V A SG11201610731V A SG 11201610731VA SG 11201610731V A SG11201610731V A SG 11201610731VA SG 11201610731V A SG11201610731V A SG 11201610731VA SG 11201610731V A SG11201610731V A SG 11201610731VA
Authority
SG
Singapore
Prior art keywords
dengue virus
fragments
immunogenic composition
structural proteins
composition against
Prior art date
Application number
SG11201610731VA
Other languages
English (en)
Inventor
Frédéric Tangy
Anavaj Shakuntabai
Etienne Simon-Loriere
Claude Roth
Philippe Buchy
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut
Publication of SG11201610731VA publication Critical patent/SG11201610731VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201610731VA 2014-06-23 2015-06-22 A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection SG11201610731VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305984.8A EP2959915A1 (en) 2014-06-23 2014-06-23 A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
PCT/EP2015/064010 WO2015197565A1 (en) 2014-06-23 2015-06-22 A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection

Publications (1)

Publication Number Publication Date
SG11201610731VA true SG11201610731VA (en) 2017-01-27

Family

ID=51062758

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201610731VA SG11201610731VA (en) 2014-06-23 2015-06-22 A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection

Country Status (12)

Country Link
US (2) US10316066B2 (pt)
EP (2) EP2959915A1 (pt)
JP (1) JP6486973B2 (pt)
KR (1) KR102557390B1 (pt)
CN (1) CN107074913B (pt)
AU (1) AU2015279375B2 (pt)
BR (1) BR112016030326B1 (pt)
CA (1) CA2952531C (pt)
MX (1) MX2017000169A (pt)
PH (1) PH12016502554A1 (pt)
SG (1) SG11201610731VA (pt)
WO (1) WO2015197565A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3331559A4 (en) 2015-08-03 2019-03-06 The United States of America as represented by the Secretary of the Army, Walter Reed Army Institute Of Research (WRAIR) PROTEIN OF RECOMBINANT DENGUE ENHANCING IMMUNITY
CN105801674B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p7及其应用
CN105777877B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p4及其应用
EP3474892A1 (en) 2016-06-24 2019-05-01 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
SG11202004234SA (en) * 2017-11-09 2020-06-29 Pasteur Institut A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
CN111556896A (zh) 2017-12-21 2020-08-18 株式会社绿色生物医药 交叉免疫抗原疫苗及其制备方法
US20220001001A1 (en) * 2018-07-13 2022-01-06 University Of Georgia Research Foundation Broadly reactive immunogens of dengue virus, compositions, and methods of use thereof
WO2022049595A1 (en) * 2020-09-01 2022-03-10 Helmholtz Zentrum für Infektionsforschung GmbH Multi-patch vaccines and immunogenic compositions, methods of production and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3688290B2 (ja) 1991-11-21 2005-08-24 コモン サーヴィシス エージェンシー Ｃ型肝炎ウイルス検査
ES2427139T3 (es) 2002-06-20 2013-10-29 Institut Pasteur Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna
DE60233038D1 (de) 2002-06-20 2009-09-03 Pasteur Institut Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen
ZA200900483B (en) * 2006-07-14 2010-03-31 Sanofi Pasteur Biologics Co Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
EP2545071A2 (en) * 2010-03-09 2013-01-16 Maksyutov, Amir Polyepitope constructs and methods for their preparation and use
WO2011163628A2 (en) * 2010-06-24 2011-12-29 La Jolla Institute For Allergy And Immunology Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof
WO2012178196A2 (en) * 2011-06-24 2012-12-27 La Jolla Institute For Allergy And Immunology Protection against dengue virus and prevention of severe dengue disease

Also Published As

Publication number Publication date
US20190300578A1 (en) 2019-10-03
EP3157555A1 (en) 2017-04-26
WO2015197565A1 (en) 2015-12-30
US10316066B2 (en) 2019-06-11
JP2017520252A (ja) 2017-07-27
JP6486973B2 (ja) 2019-03-20
BR112016030326B1 (pt) 2023-10-31
KR102557390B1 (ko) 2023-07-19
PH12016502554B1 (en) 2017-04-10
CA2952531C (en) 2021-12-28
US20170158740A1 (en) 2017-06-08
CA2952531A1 (en) 2015-12-30
BR112016030326A2 (pt) 2017-10-24
EP3157555B1 (en) 2024-05-15
PH12016502554A1 (en) 2017-04-10
MX2017000169A (es) 2017-06-29
AU2015279375A1 (en) 2017-01-05
US11034730B2 (en) 2021-06-15
KR20170020513A (ko) 2017-02-22
EP2959915A1 (en) 2015-12-30
AU2015279375B2 (en) 2019-06-13
CN107074913B (zh) 2022-02-25
CN107074913A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
SG11201610731VA (en) A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
HK1247636A1 (zh) Rna指導的人類jc病毒和其他多瘤病毒的根除
ZA201701851B (en) Fmdv recombinant vaccines and uses thereof
HUS2300022I1 (hu) Készítmények és eljárások vakcinák dengue vírus kiméra-konstrukcióihoz
ZA201700165B (en) Influenza virus vaccines and uses thereof
SG11201606624WA (en) Antibody moleules to dengue virus and uses thereof
EP2985288A4 (en) PIGS PSEUDORABIESVIRUS, VACCINE COMPOSITION, AND METHOD OF PREPARATION AND USE THEREOF
SG11201610443WA (en) Influenza virus vaccines and uses thereof
SG11201702116VA (en) Viral rna segments as immunomodulatory agents and vaccine components
SG11201703366RA (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
HK1255379A1 (zh) 丙型肝炎病毒免疫原性組合物及其使用方法
IL287985A (en) A peptide derived from koc1 and a component containing it
SG11201510266SA (en) Dengue virus vaccine compositions and methods of use thereof
HK1244534A1 (zh) 重組疏螺旋體蛋白及其使用方法
SG11202004234SA (en) A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
SG11201510617WA (en) Methods and compositions for dengue virus vaccines
SG11201505930TA (en) Porcine parvovirus 5b, methods of use and vaccine
SG11201704942QA (en) Dengue virus vaccine compositions and methods of use thereof
SG11201706342PA (en) An epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
EP3131875A4 (en) Allenamide as an orthogonal handle for selective modification of cysteine in peptides and proteins
PT3157918T (pt) Derivados de 2-aril-4-hidroxi-1,3-tiazole úteis como inibidores de trpm8 no tratamento de neuralgia, dor, dpoc e asma
SG11201606237RA (en) Hcv chimeric vaccine with influenza virus as vector and preparation method thereof
IL249704A0 (en) Influenza virus vaccines and their uses
IL249705B (en) Influenza virus vaccines and their uses
TH1501005277A (th) องค์ประกอบ และวิธีการสำหรับชุดโครงสร้างไคมีริกไวรัสเด็งกีในวัคซีน